all-trans-retinoic acid + interferon alfa-2a + tamoxifen

The drug "all-trans-retinoic acid + interferon alfa-2a + tamoxifen" is a combination therapy consisting of three distinct medications, each with its own mechanism of action and properties. All-trans-retinoic acid (ATRA) is a vitamin A derivative used to treat acute promyelocytic leukemia (APL) and various skin conditions. It works by causing immature leukemia cells to mature and differentiate, slowing cancer growth[1][3][5][7]. ATRA is taken orally as capsules that should be swallowed whole with water[3][7]. Tamoxifen is a selective estrogen receptor modulator (SERM) primarily used to treat estrogen receptor-positive breast cancer. It works by blocking estrogen activity in breast tissue, which can inhibit the growth of certain breast tumors[6][8][10]. Tamoxifen is typically taken orally as tablets. While interferon alfa-2a is not specifically described in the search results, it's known to be a biologic agent with immunomodulatory, antiviral, and antineoplastic properties. This combination therapy appears to target cancer through multiple mechanisms: ATRA promotes cell differentiation, tamoxifen blocks estrogen-dependent growth pathways, and interferon alfa-2a likely provides immunomodulatory effects. The search results don't provide specific information about this exact combination being used together as a standard treatment regimen, nor do they mention specific clinical trials or approval status for this particular combination.

Other names

ATRA + interferon alfa-2a + tamoxifen